Patent intelligence · US
US 8187817
Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies
Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies
Patent details — US 8187817
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 29, 2012
- Expiration
- May 24, 2032
- Applicant
- XBIOTECH INC.
- Claims
- 14
- CPC classes
- A61P, A61P9/00, A61P9/10
Quick answer
US 8187817 (Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies) is held by XBIOTECH INC.. Status: granted. Granted May 29, 2012. Expires May 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XBIOTECH INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61P, A61P9/00, A61P9/10
More from XBIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 12116405
Arthritis treatment
granted -
US 11932688
Treatment for neoplastic diseases
granted -
US 11773157
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 11529298
Cosmetic composition and its use, dermocosmetic formulation
granted -
US 11523981
Cosmetic composition and its use, dermocosmetic formulation
granted -
US 11370831
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10577410
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10294296
Treatment for neoplastic diseases
granted
Frequently asked questions
What is US patent 8187817?
US 8187817 (Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies) is held by XBIOTECH INC.. Status: granted. Granted May 29, 2012. Expires May 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8187817?
XBIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.
When does US 8187817 expire?
Our index shows an expiration date of May 24, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.